S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
NYSE:PKI

PerkinElmer - PKI Stock Forecast, Price & News

$130.35
-1.00 (-0.76%)
(As of 10/6/2022 10:28 AM ET)
Add
Compare
Today's Range
$130.10
$131.45
50-Day Range
$118.07
$160.96
52-Week Range
$116.18
$203.16
Volume
3,397 shs
Average Volume
793,554 shs
Market Capitalization
$16.45 billion
P/E Ratio
24.41
Dividend Yield
0.22%
Price Target
$162.50

PerkinElmer MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
22.2% Upside
$160.50 Price Target
Short Interest
Healthy
4.29% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.59mentions of PerkinElmer in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.35 M Sold Last Quarter
Proj. Earnings Growth
-16.09%
From $7.83 to $6.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Computer And Technology Sector

150th out of 631 stocks

Analytical Instruments Industry

6th out of 29 stocks

PKI stock logo

About PerkinElmer (NYSE:PKI) Stock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

PerkinElmer (NYSE:PKI) Lowered to C+ at TheStreet
TheStreet Lowers PerkinElmer (NYSE:PKI) to C+
PerkinElmer (NYSE:PKI) Rating Lowered to C+ at TheStreet
PerkinElmer (NYSE:PKI) Lowered to "C+" at TheStreet
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
See More Headlines
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Ex-Dividend for 8/12 Dividend
7/21/2022
Last Earnings
8/01/2022
Dividend Payable
8/12/2022
Today
10/06/2022
Ex-Dividend for 11/11 Dividend
10/20/2022
Next Earnings (Estimated)
11/01/2022
Dividend Payable
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$160.50
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+24.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

Net Income
$943.16 million
Pretax Margin
18.24%

Debt

Sales & Book Value

Annual Sales
$5.07 billion
Cash Flow
$13.90 per share
Book Value
$56.59 per share

Miscellaneous

Free Float
125,568,000
Market Cap
$16.45 billion
Optionable
Optionable
Beta
1.15

Social Links


Key Executives

  • Dr. Prahlad R. Singh Ph.D. (Age 57)
    CEO, Pres & Director
    Comp: $4.15M
  • Mr. James M. MockMr. James M. Mock (Age 45)
    Sr. VP & CFO
    Comp: $1.6M
  • Mr. Tajinder Vohra (Age 56)
    Sr. VP of Global Operations
    Comp: $1.06M
  • Mr. Joel S. GoldbergMr. Joel S. Goldberg (Age 53)
    Sr. VP of Admin., Gen. Counsel & Sec.
    Comp: $1.53M
  • Mr. Daniel R. TereauMr. Daniel R. Tereau (Age 54)
    Sr. VP of Strategy & Bus. Devel.
    Comp: $1.18M
  • Mr. Andrew OkunMr. Andrew Okun (Age 52)
    VP, Chief Accounting Officer & Treasurer
  • Mr. Stephen Barr Willoughby
    VP of Investor Relations
  • Mr. Robert Francis Friel (Age 66)
    Advisor
  • Ms. Miriame Victor (Age 41)
    Sr. VP & Chief Commercial Officer
  • Dr. Masoud Toloue Ph.D. (Age 42)
    Sr. VP of Diagnostics













PKI Stock - Frequently Asked Questions

Should I buy or sell PerkinElmer stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PKI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PKI, but not buy additional shares or sell existing shares.
View PKI analyst ratings
or view top-rated stocks.

What is PerkinElmer's stock price forecast for 2022?

9 equities research analysts have issued 12-month target prices for PerkinElmer's shares. Their PKI share price forecasts range from $50.00 to $205.00. On average, they anticipate the company's share price to reach $162.50 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts price targets for PKI
or view top-rated stocks among Wall Street analysts.

How have PKI shares performed in 2022?

PerkinElmer's stock was trading at $201.06 at the start of the year. Since then, PKI stock has decreased by 34.7% and is now trading at $131.35.
View the best growth stocks for 2022 here
.

When is PerkinElmer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PKI earnings forecast
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its earnings results on Monday, August, 1st. The medical research company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.29. The medical research company earned $1.23 billion during the quarter, compared to analysts' expectations of $1.20 billion. PerkinElmer had a trailing twelve-month return on equity of 16.68% and a net margin of 13.21%. PerkinElmer's revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the company earned $2.83 EPS.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Friday, July 22nd. Investors of record on Friday, October 21st will be paid a dividend of $0.07 per share on Friday, November 11th. This represents a $0.28 annualized dividend and a yield of 0.21%. The ex-dividend date is Thursday, October 20th.
Read our dividend analysis for PKI
.

Is PerkinElmer a good dividend stock?

PerkinElmer (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.22%. The dividend payout ratio is 5.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of $1.40-$1.45 for the period, compared to the consensus EPS estimate of $1.34. The company issued revenue guidance of $1.02 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wedmont Private Capital (0.00%), First Hawaiian Bank (0.00%) and AdvisorNet Financial Inc (0.00%). Insiders that own company stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends
.

How do I buy shares of PerkinElmer?

Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $131.35.

How much money does PerkinElmer make?

PerkinElmer (NYSE:PKI) has a market capitalization of $16.58 billion and generates $5.07 billion in revenue each year. The medical research company earns $943.16 million in net income (profit) each year or $5.34 on an earnings per share basis.

How many employees does PerkinElmer have?

The company employs 16,700 workers across the globe.

Does PerkinElmer have any subsidiaries?
The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More
How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.